COLLEGIUM PHARMACEUTICAL, INC — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Vikram Karnani (CEO) and Colleen Tupper (CFO) executed standard Sarbanes-Oxley Section 302 and 906 certifications on August 6, 2026 for the Q2 2026 10-Q filing. Both officers certified that the report contains no material misstatements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are designed and operating effectively. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine boilerplate SOX certification exhibits. No operational changes, financial data, transactions, or control issues disclosed. Standard periodic compliance filing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.